Skip to main content

Featured

Global Markets Reel as Wall Street Suffers Sharpest Fall Since Iran Conflict Began

Wall Street endured its steepest decline since the outbreak of the Iran war, as renewed uncertainty over diplomatic progress sent shockwaves through global markets. The S&P 500 plunged 1.7% , marking its worst day since January and extending a five‑week losing streak , the longest in nearly four years. The Dow Jones Industrial Average fell 469 points , while the Nasdaq dropped 2.4% , slipping more than 10% below its record high — a threshold investors label a correction .  The downturn followed conflicting signals about potential ceasefire negotiations. While U.S. officials suggested Iran was open to talks, Tehran publicly denied direct engagement and dismissed a U.S. proposal delivered via Pakistan. The resulting uncertainty pushed oil prices sharply higher , with Brent crude rising 4.8% to $101.89 , up from roughly $70 before the conflict. Global markets echoed the volatility, with major indexes across Asia and Europe also tumbling. Analysts warn that Iran’s tightening con...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment